XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.24.3

Revenue Recognition (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Timing of Revenue Recognition | The following table illustrates the timing of the Company’s revenue recognition patterns:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Software products and services – point in time | 40.3 | % |  | 37.0 | % |  | 43.0 | % |  | 36.8 | %
Software products and services – over time | 50.0 |  |  | 30.9 |  |  | 41.5 |  |  | 26.6 |
Drug Discovery – point in time | — |  |  | — |  |  | 7.6 |  |  | 19.1 |
Drug Discovery – over time | 9.7 |  |  | 32.1 |  |  | 7.9 |  |  | 17.5 |
Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue | The following table presents the revenue recognized from the sources of software products and services revenue:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
On-premise software | $ | 12,250 |  |  | $ | 13,806 |  |  | $ | 48,627 |  |  | $ | 50,564 |
Hosted software | 8,814 |  |  | 5,463 |  |  | 24,077 |  |  | 14,366 |
Software maintenance | 5,658 |  |  | 5,752 |  |  | 17,393 |  |  | 17,378 |
Professional services | 2,038 |  |  | 2,083 |  |  | 7,482 |  |  | 6,361 |
Revenue from contracts with customers | 28,760 |  |  | 27,104 |  |  | 97,579 |  |  | 88,669 |
Software contribution | 3,124 |  |  | 1,800 |  |  | 3,124 |  |  | 1,800 |
Total software revenue | $ | 31,884 |  |  | $ | 28,904 |  |  | $ | 100,703 |  |  | $ | 90,469 |
Drug Discovery Revenue | The following table presents the revenue recognized from the sources of drug discovery revenue:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Drug discovery services revenue from contracts with customers | $ | 2,813 |  |  | $ | 12,730 |  |  | $ | 17,012 |  |  | $ | 49,765 |
Drug discovery contribution | 593 |  |  | 935 |  |  | 1,507 |  |  | 2,306 |
Total drug discovery revenue | $ | 3,406 |  |  | $ | 13,665 |  |  | $ | 18,519 |  |  | $ | 52,071 |
Schedule of Contract Balances | Contract balances were as follows:
| As of September 30, 2024 |  | As of December 31, 2023
Contract assets | $ | 30,528 |  |  | $ | 21,107 |
Deferred revenue, short-term: |  |  |
Software products and services | 32,978 |  |  | 44,218 |
Drug discovery | 8,795 |  |  | 12,013 |
Deferred revenue, long-term: |  |  |
Software products and services | 1,862 |  |  | 2,407 |
Drug discovery | 3,338 |  |  | 6,636 |

X
- Definition Drug discovery revenue. + References No definition available. + Details
Name: | sdgr_DrugDiscoveryRevenueTableTableTextBlock
Namespace Prefix: | sdgr_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration